|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Copeptin and insulin-like growth factor binding protein-1 were analysed in patients (median age = 70, male = 68%) with type 2 diabetes mellitus + myocardial infarction at admission (n = 393), discharge (n = 309) and 3 months later (n = 288).
|
30309264 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of arginine vasopressin in myocardial infarction and reperfusion.
|
31553327 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The negative predictive value of copeptin at a cut-off of 14 pmol/l (as in the CHOPIN study) for myocardial infarction was higher in Blacks (98.0%, 95% confidence interval (CI) 96.2-99.1%) than Caucasians (94.1%, 95% CI 92.1-95.7%).
|
29737180 |
2019 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac specific troponin T (cTnT) and the endogenous stress marker copeptin have different temporal release patterns for myocardial infarction MI.
|
29932892 |
2018 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Copeptin levels in conjunction with cardiac troponin may be used to rule out early myocardial infarction in patients presenting with chest pain.
|
29750698 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cox proportional hazards survival regression analyses confirmed the association of copeptin with cardiovascular events in both cohorts: hazard ratio with 95% confidence interval for T3 vs. T1 was 1.29 (1.04-1.59), p = 0.02 (DIABHYCAR), and 1.58 (1.23-2.04), p = 0.0004 (SURDIAGENE), adjusted for sex, age, BMI, duration of diabetes, systolic blood pressure, arterial hypertension, HbA1c, total cholesterol, HDL-cholesterol, triglycerides, estimated glomerular filtration rate (eGFR), urinary albumin concentration (UAC), active tobacco smoking, and previous history of myocardial infarction at baseline.
|
30071874 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
As MI and AAS share presenting symptoms, stress mechanisms and necessity for rapid diagnosis, copeptin appears as an attractive biomarker also for AAS.
|
30425269 |
2018 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Copeptin is a marker of endogenous stress including early myocardial infarction(MI) and has value in early rule out of MI when used with cardiac troponin I(cTnI).
|
27847253 |
2017 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, copeptin has been shown to be associated with increased risk of complications such as myocardial infarction, heart failure, diabetes mellitus and metabolic syndrome.
|
28714397 |
2017 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, there were no significant associations of ADH genetic polymorphisms to CAD and MI risks (CAD: RR=0.92, 95%CI: 0.73-1.15, P=0.445; MI: RR=0.93, 95%CI: 0.84-1.03, P=0.148).
|
23685282 |
2013 |